Publications

European journal of cancer (Oxford, England : 1990)

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

01-07-2021

Nature medicine

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

01-07-2021

Journal of translational medicine

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).

30-06-2021

Cancers

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors.

05-06-2021

The Lancet. Oncology

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

01-06-2021

Annals of oncology : official journal of the European Society for Medical Oncology

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

01-06-2021

The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

01-05-2021

Annals of internal medicine

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

01-05-2021

European journal of cancer (Oxford, England : 1990)

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

01-05-2021

The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

01-05-2021

British journal of cancer

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-05-2021

Nature medicine

COVID-19 vaccination: the VOICE for patients with cancer.

01-04-2021

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reply to E. Hindié.

10-03-2021

British journal of cancer

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-03-2021

British journal of cancer

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

01-02-2021

American journal of clinical oncology

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.

01-02-2021

Nature medicine

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

01-02-2021

Nature medicine

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

01-02-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.

15-01-2021

Acta oncologica (Stockholm, Sweden)

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

01-01-2021

Journal for immunotherapy of cancer

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

01-01-2021

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Key Publication

Journal for immunotherapy of cancer

Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

01-12-2020

Journal of autoimmunity

Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.

01-12-2020

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.

20-11-2020

ESMO open

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.

01-11-2020

Annals of oncology : official journal of the European Society for Medical Oncology

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.

01-11-2020

Annals of oncology : official journal of the European Society for Medical Oncology

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.

01-11-2020

Journal of translational medicine

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).

07-09-2020

Nature communications

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-08-2020

Journal for immunotherapy of cancer

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach.

01-08-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy^☆.

01-08-2020

Journal for immunotherapy of cancer

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.

01-08-2020

Cancers

Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response.

27-07-2020

Nature medicine

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

01-07-2020

Melanoma research

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).

01-06-2020

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Prognostic and predictive role of the tumor immune landscape.

01-06-2020

Science (New York, N.Y.)

The human tumor microbiome is composed of tumor type-specific intracellular bacteria.

29-05-2020

Journal of cancer research and therapeutics

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.

05-05-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

01-05-2020

Pigment cell & melanoma research

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.

01-05-2020

Clinical and experimental rheumatology

Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report.

18-04-2020

JAMA oncology

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

01-04-2020

European urology oncology

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.

01-04-2020

Nature medicine

Learning from clinical trials of neoadjuvant checkpoint blockade.

01-04-2020

Oncoimmunology

Lactate dehydrogenase: a marker of diminished antitumor immunity.

12-03-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.

01-01-2020

Nature

B cells and tertiary lymphoid structures promote immunotherapy response.

01-01-2020

European journal of cancer (Oxford, England : 1990)

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

01-01-2020

Nature medicine

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

01-12-2019

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors.

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

COVID-19 vaccination: the VOICE for patients with cancer.

Reply to E. Hindié.

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach.

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆.

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.

Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response.

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).

Prognostic and predictive role of the tumor immune landscape.

The human tumor microbiome is composed of tumor type-specific intracellular bacteria.

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.

Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.

Learning from clinical trials of neoadjuvant checkpoint blockade.

Lactate dehydrogenase: a marker of diminished antitumor immunity.

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.

B cells and tertiary lymphoid structures promote immunotherapy response.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

This site uses cookies

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy^☆.